Development of PEA-15 using a potent non-viral vector for therapeutic application in breast cancer

Cancer Letters

Volumn 356, Issue 2, 2015, Pages 374-381

  Xie, Xinhua ^a   Tang, Hailin ^a   Liu, Peng ^a   Kong, Yanan ^a   Wu, Minqing ^a   Xiao, Xiangsheng ^a   Yang, Lu ^a   Gao, Jie ^a   Wei, Weidong ^a   Lee, Jangsoon ^b   Bartholomeusz, Chandra ^b   Ueno, Naoto T ^b   Xie, Xiaoming ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Breast cancer; PEA 15; T VISA system; Target therapy

Indexed keywords

LIPOSOME; NANOPARTICLE; PROTEIN PEA 15; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; PEA15 PROTEIN, HUMAN; PHOSPHOPROTEIN; SIGNAL PEPTIDE; TELOMERASE; TERT PROTEIN, HUMAN;

ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CELL KILLING; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; SURVIVAL TIME; ANIMAL; BAGG ALBINO MOUSE; BREAST NEOPLASMS; DRUG SCREENING; ENZYME IMMUNOASSAY; GENE VECTOR; GENETICS; NUDE MOUSE; PATHOLOGY; PROMOTER REGION; THERAPEUTIC USE; TRANSGENE; TUMOR CELL CULTURE; WESTERN BLOTTING;

CYTOMEGALOVIRUS; MUS;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL PROLIFERATION; FEMALE; GENETIC VECTORS; HUMANS; IMMUNOENZYME TECHNIQUES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, INBRED BALB C; MICE, NUDE; PHOSPHOPROTEINS; PROMOTER REGIONS, GENETIC; TELOMERASE; TRANSGENES; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84919494948     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.09.033     Document Type: Article

References (34)

1. Siegel R., Ma J., Zou Z., Jemal A. Cancer statistics, 2014. CA Cancer J. Clin 2014, 64:9-29.
2. Dou S., Yao Y.D., Yang X.Z., Sun T.M., Mao C.Q., Song E.W., et al. Anti-Her2 single-chain antibody mediated DNMTs-siRNA delivery for targeted breast cancer therapy. J. Control. Release 2012, 161:875-883.
3. Yao Y.D., Sun T.M., Huang S.Y., Dou S., Lin L., Chen J.N., et al. Targeted delivery of PLK1-siRNA by ScFv suppresses Her2+ breast cancer growth and metastasis. Sci. Transl. Med 2012, 4. 130ra148.
4. Xie X., Guo J., Kong Y., Xie G.X., Li L., Lv N., et al. Targeted expression of Escherichia coli purine nucleoside phosphorylase and Fludara(R) for prostate cancer therapy. J. Gene Med 2011, 13:680-691.
5. Lang J.Y., Hsu J.L., Meric-Bernstam F., Chang C.J., Wang Q., Bao Y., et al. BikDD eliminates breast cancer initiating cells and synergizes with lapatinib for breast cancer treatment. Cancer Cell 2011, 20:341-356.
6. Xie X., Li L., Xiao X., Guo J., Kong Y., Wu M., et al. Targeted expression of BikDD eliminates breast cancer with virtually no toxicity in noninvasive imaging models. Mol. Cancer Ther 2012, 11:1915-1924.
7. Bartholomeusz C., Gonzalez-Angulo A.M., Kazansky A., Krishnamurthy S., Liu P., Yuan L.X., et al. PEA-15 inhibits tumorigenesis in an MDA-MB-468 triple-negative breast cancer xenograft model through increased cytoplasmic localization of activated extracellular signal-regulated kinase. Clin. Cancer Res 2010, 16:1802-1811.
8. Xie X., Bartholomeusz C., Ahmed A.A., Kazansky A., Diao L., Baggerly K.A., et al. Bisphosphorylated PEA-15 sensitizes ovarian cancer cells to paclitaxel by impairing the microtubule-destabilizing effect of SCLIP. Mol. Cancer Ther 2013, 12:1099-1111.
9. Lee J., Bartholomeusz C., Krishnamurthy S., Liu P., Saso H., Lafortune T.A., et al. PEA-15 unphosphorylated at both serine 104 and serine 116 inhibits ovarian cancer cell tumorigenicity and progression through blocking beta-catenin. Oncogenesis 2012, 1:e22.
10. Callaway K., Abramczyk O., Martin L., Dalby K.N. The anti-apoptotic protein PEA-15 is a tight binding inhibitor of ERK1 and ERK2, which blocks docking interactions at the D-recruitment site. Biochemistry 2007, 46:9187-9198.
11. Funke V., Lehmann-Koch J., Bickeboller M., Benner A., Tagscherer K.E., Grund K., et al. The PEA-15/PED protein regulates cellular survival and invasiveness in colorectal carcinomas. Cancer Lett 2013, 335:431-440.
12. Watanabe Y., Yamasaki F., Kajiwara Y., Saito T., Nishimoto T., Bartholomeusz C., et al. Expression of phosphoprotein enriched in astrocytes 15 kDa (PEA-15) in astrocytic tumors: a novel approach of correlating malignancy grade and prognosis. J. Neurooncol 2010, 100:449-457.
13. Li L., Xie X., Luo J., Liu M., Xi S., Guo J., et al. Targeted expression of miR-34a using the T-VISA system suppresses breast cancer cell growth and invasion. Mol. Ther 2012, 20:2326-2334.
14. Xie X., Xia W., Li Z., Kuo H.P., Liu Y., Li Z., et al. Targeted expression of BikDD eradicates pancreatic tumors in noninvasive imaging models. Cancer Cell 2007, 12:52-65.
15. Hu Y.L., Huang B., Zhang T.Y., Miao P.H., Tang G.P., Tabata Y., et al. Mesenchymal stem cells as a novel carrier for targeted delivery of gene in cancer therapy based on nonviral transfection. Mol. Pharm 2012, 9:2698-2709.
16. Klutz K., Willhauck M.J., Dohmen C., Wunderlich N., Knoop K., Zach C., et al. Image-guided tumor-selective radioiodine therapy of liver cancer after systemic nonviral delivery of the sodium iodide symporter gene. Hum. Gene Ther 2011, 22:1563-1574.
17. Botta G., Perruolo G., Libertini S., Cassese A., Abagnale A., Beguinot F., et al. PED/PEA-15 modulates coxsackievirus-adenovirus receptor expression and adenoviral infectivity via ERK-mediated signals in glioma cells. Hum. Gene Ther 2010, 21:1067-1076.
18. Bartholomeusz C., Rosen D., Wei C., Kazansky A., Yamasaki F., Takahashi T., et al. PEA-15 induces autophagy in human ovarian cancer cells and is associated with prolonged overall survival. Cancer Res 2008, 68:9302-9310.
19. Chou F.L., Hill J.M., Hsieh J.C., Pouyssegur J., Brunet A., Glading A., et al. PEA-15 binding to ERK1/2 MAPKs is required for its modulation of integrin activation. J. Biol. Chem 2003, 278:52587-52597.
20. Formstecher E., Ramos J.W., Fauquet M., Calderwood D.A., Hsieh J.C., Canton B., et al. PEA-15 mediates cytoplasmic sequestration of ERK MAP kinase. Dev. Cell 2001, 1:239-250.
21. Bartholomeusz C., Itamochi H., Nitta M., Saya H., Ginsberg M.H., Ueno N.T. Antitumor effect of E1A in ovarian cancer by cytoplasmic sequestration of activated ERK by PEA15. Oncogene 2006, 25:79-90.
22. Hill J.M., Vaidyanathan H., Ramos J.W., Ginsberg M.H., Werner M.H. Recognition of ERK MAP kinase by PEA-15 reveals a common docking site within the death domain and death effector domain. EMBO J. 2002, 21:6494-6504.
23. Whitehurst A.W., Robinson F.L., Moore M.S., Cobb M.H. The death effector domain protein PEA-15 prevents nuclear entry of ERK2 by inhibiting required interactions. J. Biol. Chem 2004, 279:12840-12847.
24. Renganathan H., Vaidyanathan H., Knapinska A., Ramos J.W. Phosphorylation of PEA-15 switches its binding specificity from ERK/MAPK to FADD. Biochem. J. 2005, 390:729-735.
25. Trencia A., Perfetti A., Cassese A., Vigliotta G., Miele C., Oriente F., et al. Protein kinase B/Akt binds and phosphorylates PED/PEA-15, stabilizing its antiapoptotic action. Mol. Cell. Biol 2003, 23:4511-4521.
26. Sulzmaier F., Opoku-Ansah J., Ramos J.W. Phosphorylation is the switch that turns PEA-15 from tumor suppressor to tumor promoter. Small GTPases 2012, 3:173-177.
27. Quintavaller C., Costanzo S., Zanca C., Tasset I., Fraldi A., Incoronato M., et al. Phosphorylation-regulated degradation of the tumor-suppressor form of PED by chaperone-mediated autophagy in lung cancer cells. J. Cell. Physiol 2014, 229:1359-1368.
28. Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature 2012, 490:61-70.
29. Sher Y.P., Chang C.M., Juo C.G., Chen C.T., Hsu J.L., Lin C.Y., et al. Targeted endostatin-cytosine deaminase fusion gene therapy plus 5-fluorocytosine suppresses ovarian tumor growth. Oncogene 2013, 32:1082-1090.
30. Shen H., Mittal V., Ferrari M., Chang J. Delivery of gene silencing agents for breast cancer therapy. Breast Cancer Res 2013, 15:205.
31. Steidl U., Steidl C., Ebralidze A., Chapuy B., Han H.J., Will B., et al. A distal single nucleotide polymorphism alters long-range regulation of the PU.1 gene in acute myeloid leukemia. J. Clin. Invest 2007, 117:2611-2620.
32. Giacca M., Zacchigna S. Virus-mediated gene delivery for human gene therapy. J. Control. Release 2012, 161:377-388.
33. Rogers M.L., Rush R.A. Non-viral gene therapy for neurological diseases, with an emphasis on targeted gene delivery. J. Control. Release 2012, 157:183-189.
34. Glading A., Koziol J.A., Krueger J., Ginsberg M.H. PEA-15 inhibits tumor cell invasion by binding to extracellular signal-regulated kinase 1/2. Cancer Res 2007, 67:1536-1544.